6 days Ago By ABMN Staff
Franklin Resources Inc. reduced its position in shares of Applied Therapeutics, Inc. ( NASDAQ:APLT – Free Report ) by 70.
5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,003,400 shares of the company’s stock after selling 4,797,510 shares during the period. Franklin Resources Inc.
owned about 1.72% of Applied Therapeutics worth $1,715,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently modified their holdings of the company.
Private Advisor Group LLC acquired a new stake in Applied Therapeutics during the fourth quarter worth approximately $35,000. SG Americas Securities LLC raised its stake in Applied Therapeutics by 169.0% during the 4th quarter.
SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after acquiring an additional 25,601 shares in the last quarter. Intech Investment Management LLC lifted its position in Applied Therapeutics by 176.1% in the fourth quarter.
Intech Investment Management LLC now owns 52,631 shares of the company’s stock valued at $45,000 after acquiring an additional 33,567 shares during the last quarter. Swiss National Bank acquired a new position in Applied Therapeutics in the fourth quarter valued at $126,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Applied Therapeutics during the third quarter worth about $149,000.
Institutional investors and hedge funds own 98.31% of the company’s stock. Applied Therapeutics Price Performance Applied Therapeutics stock opened at $0.
37 on Tuesday. The business has a 50 day simple moving average of $0.50 and a 200-day simple moving average of $3.
23. Applied Therapeutics, Inc. has a 12 month low of $0.
30 and a 12 month high of $10.62. The stock has a market capitalization of $42.
94 million, a PE ratio of -0.23 and a beta of 1.88.
Wall Street Analysts Forecast Growth APLT has been the subject of a number of research analyst reports. William Blair cut Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 23rd. Royal Bank of Canada reduced their price target on shares of Applied Therapeutics from $4.
00 to $1.50 and set a “sector perform” rating for the company in a research report on Friday, December 20th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company.
Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.10. View Our Latest Analysis on APLT About Applied Therapeutics ( Free Report ) Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. See Also Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
